Welcome to Medipharma Licensing limited
Medipharma Licensing Limited’s mission is to expand medical and pharmaceutical product marketing and sales in Asia and China for small and middle size pharmaceutical companies in Europe and United States
Medical and Pharmaceutical Product Licensing Strategies
- Strategic Alliance or Partnership
- Technology Transfer
- Loyalty
- Merge and Acquisition
- In licensing to Asia and China Pharmaceutical Market with existing sales channels
- Registering as import medical and pharmaceutical products to the host countries.
- Profit Sharing
- We increase your medipharma product sales in Asia and China by exports/imports mechanism.
Vision
Bridging the fast growing pharmaceutical demands in Asian and China with approved medicines in Europe and USA from small and middle size pharmaceutical companies.
In the past 3 years, FDA and EMA approved 100+ new medical and pharmaceutical products.
In Asian region including China, less than a couple new medicines are approved per year.
US EU Pharma R&D spending was 150+ Billion USD in 2016 (Evaluate Group)
China Pharma R&D spending was 7.17 Billion USD in 2016 ( Brooking Institute)
Unique market entry for small and middle size pharmaceutical companies to capture a huge market outside of USA or Europe.
Potentially no or low marketing cost for a large healthcare market.
Licensed Midepharma productsfrom USA and EU to Asia and China
- CDIBP in-licenses conjugate vaccine technology from Fina Biotech (USA)
- Luqa Pharma in-licenses scar treatment from Stratpharma (Europe)
- PharmaEngine in-licenses cancer product from Nanobiotix (Europe)
- Suzhou Connect Biopharma in-licenses anti-inflammatory drugs from Arena (USA)
- Lee’s Pharma in-licenses therapeutic peptide from RegeneRx (USA)
- Ascletis in-licenses cancer RNAi drug from Alnylam (USA)
- WIBF and Refine Technology collaborate on vaccines (USA)
- Xiangxue Pharma in-licenses cancer drug from Kinex Pharma (USA)
- BGI enters Rare Diseases Project with Children’s Hospital (USA)
- BGI expands R&D pact with GE Healthcare (USA)
- Zhifei Biological expands vaccine partnership with Merck (USA)
- Zhejiang Conba Pharma in-licenses EVT 401 to Evotec (Europe)
- Hisun enters strategic alliance with Enzon (USA)
- Conba Pharmaceutical in-licenses drug from Evotec (Europe)
- Gansu Duyiweii in-licenses antibody form Apexigen (USA)
- Hua Medicine to develop first Chinese-tailored diabetes drug with Roche (Europe)
- Tasly enters JV with and SemBioSys (Canada)
- BioDuro enters R&D deal with Dow (USA)
- Pioneer in-licenses NeutroPhase from NovaBay (USA)
- Hutchison MediPharma in cancer deal with AstraZeneca (Europe)
- Simcere in partnership to develop cardiovascular compound with BMS (USA)
- Lansen Pharma in-licenses China rights to rheumatoid drug from Ethypharm SA (Europe)
Service scopeMedical and pharmaceutical products licensing service
Licensing Partnership Due Diligences
Dossier Registration in Host Countries
Medical and Pharmaceutical Products Import Permit
Medical and Pharmaceutical Products Technology Transfer
Medical and Pharmaceutical Products Market Intelligence
Introduce, Mediate and Establish Partnerships
Management
Executives from Medipharma Licensing Limited are channel specialists with Asia and China market access for European and U.S. medical and pharmaceutical products.
Alliance
Medipharma Licensing Limited is passionate to partner your products with Asia and China sales networks.
